DrugPatentWatch Database Preview

Details for Patent: 7,745,409

« Back to Dashboard

Which drugs does patent 7,745,409 protect, and when does it expire?

Patent 7,745,409 protects LINZESS and is included in one NDA.

This patent has seventy-four patent family members in twenty-four countries.

Summary for Patent: 7,745,409

Title:	Methods and compositions for the treatment of gastrointestinal disorders
Abstract:	The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Inventor(s):	Currie; Mark G. (Sterling, MA), Mahajan-Miklos; Shalina (Stanford, CA), Norman; Thea (San Diego, CA), Milne; G. Todd (Brookline, MA)
Assignee:	Ironwood Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	11/949,340
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,745,409
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 7,745,409

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Allergan Sales Llc	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017		RX	Yes	No			Y	Y
Allergan Sales Llc	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012		RX	Yes	No			Y	Y
Allergan Sales Llc	LINZESS	linaclotide	CAPSULE;ORAL	202811-002	Aug 30, 2012		RX	Yes	Yes			Y	Y

Non-Orange Book US Patents Family Members for Patent 7,745,409

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,772,188	Methods and compositions for the treatment of gastrointestinal disorders
8,080,526	Methods and compositions for the treatment of gastrointestinal disorders
8,110,553	Methods and compositions for the treatment of gastrointestinal disorders
7,304,036	Methods and compositions for the treatment of gastrointestinal disorders

International Family Members for US Patent 7,745,409

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Russian Federation	2353383
Russian Federation	2005127058
Portugal	2246360
Mexico	PA06010205